ABT-126 Compared With Placebo for Cognitive Difficulties in Schizophrenia
About this title
Read the official source — NCT01678755Researchers compared ABT-126 and placebo to find out how the approaches affected memory, attention and other thinking skills in people with schizophrenia.
Understand this study
What did researchers investigate?
Researchers compared ABT-126 and placebo to find out how the approaches affected memory, attention and other thinking skills in people with schizophrenia.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 20 years to 55 years. Other eligibility criteria applied.
- Listed locations
- Chino and 19 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
- Recruitment status
- Completed
- Enrollment listed in the registry
- 157
- Sponsor
- AbbVie (prior sponsor, Abbott)
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 20 Years to 55 Years
- Official registry ID
- NCT01678755
- Official title
Show the full official title
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS) in Smokers
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
Chino · Garden Grove · National City
17 more locations
- Oceanside
- Orange
- San Diego
- Torrance
- Bradenton
- Maitland
- Atlanta
- Chicago
- Hoffman Estates
- Lake Charles
- St Louis
- Marlton
- Cedarhurst
- New York
- Oklahoma City
- DeSoto
- Houston
Interested in joining this study?
Questions about this study
What did researchers investigate?
Researchers compared ABT-126 and placebo to find out how the approaches affected memory, attention and other thinking skills in people with schizophrenia.
Who is behind this study?
The study sponsor is AbbVie (prior sponsor, Abbott).
Did this study involve medication?
Yes. The study involved medication, including ABT-126 and Placebo.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 20 years to 55 years. Other eligibility criteria applied.
